Several Phase I trials evaluating the use of siRNA for the treatment of solid cancers have now been completed.
All trials to date have used nanoparticle-based delivery systems to transport therapeutic siRNA to tumours following systemic administration.
Despite concerns about potential overwhelming immunostimulation following systemic siRNA administration in humans, the data reported to date for clinically evaluated siRNA therapeutics (both naked and chemically modified siRNA) have shown these therapeutics to be well tolerated, with only modest and treatable immunostimulatory reactions.
Successful delivery of functional siRNA to human tumours has been demonstrated in multiple trials, providing proof-of-principle for RNAi- based therapeutics in humans.
Results from these trials show that safe target gene inhibition can be achieved in patients, when systemically treated twice per week with either lipid- or polymer-based nanoparticle formulations containing siRNAs at doses in the 0.5–1.0 mg siRNA per kg range.
Small interfering RNA (siRNA)-based therapies are emerging as a promising new anticancer approach, and a small number of Phase I clinical trials involving patients with solid tumours have now been completed. Encouraging results from these pioneering clinical studies show that these new therapeutics can successfully and safely inhibit targeted gene products in patients with cancer, and have taught us important lessons regarding appropriate dosages and schedules. In this Review, we critically assess these Phase I studies and discuss their implications for future clinical trial design. Key challenges and future directions in the development of siRNA-containing anticancer therapeutics are also considered.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
European Journal of Medical Research Open Access 08 October 2022
CD73 downregulation by EGFR-targeted liposomal CD73 siRNA potentiates antitumor effect of liposomal doxorubicin in 4T1 tumor-bearing mice
Scientific Reports Open Access 21 June 2022
Molecular Cancer Open Access 11 April 2022
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Fire, A. Z. Gene silencing by double-stranded RNA (Nobel Lecture). Angew. Chem. Int. Ed. 46, 6966–6984 (2007). This paper provides a brief history and background on RNAi.
Burnett, J. C. & Rossi, J. J. RNA-based therapeutics: current progress and future prospects. Chem. Biol. 19, 60–71 (2012).
Vaishnaw, A. K. et al. A status report on RNAi therapeutics. Silence 1, 14 (2010).
de Fougerolles, A., Vornlocher, H.-P., Maraganore, J. & Lieberman, J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6, 443–453 (2007).
Sepp-Lorenzino, L. & Ruddy, M. K. Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides. Clin. Pharmacol. Ther. 84, 628–632 (2008).
Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8, 129–138 (2009).
Chen, S.-H. & Zhaori, G. Potential clinical applications of siRNA technique: benefits and limitations. Eur. J. Clin. Invest. 41, 221–232 (2011).
Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G. & Sood, A. K. RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer 11, 59–67 (2011).
Wu, S. Y., Lopez-Berestein, G., Calin, G. A. & Sood, A. K. RNAi therapies: drugging the undruggable. Sci. Transl. Med. 6, 240ps7 (2014).
Davis, M. E., Chen, Z. G. & Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771–782 (2008). This paper reviews the area of nanoparticle-based anticancer therapeutics.
Egusquiaguirre, S. P., Igartua, M. Hernández, R. M. & Pedraz, J. L. Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin. Transl. Oncol. 14, 83–93 (2012). This paper reviews the different types of delivery of siRNA and the materials used to facilitate the delivery of siRNA.
Kanasty, R., Dorkin, J. R., Vegas, A. & Anderson, D. Delivery materials for siRNA therapeutics. Nat. Mater. 12, 967–977 (2013).
Gomes da Silva, L. C., Simões, S. & Moreira, J. N. Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology. Cell. Mol. Life Sci. 21, 1417–1438 (2014).
Behlke, M. A. Chemical modification of siRNAs for in vivo use. Oligonucleotides 18, 305–320 (2008).
Rettig, G. R. & Behlke, M. A. Progress toward in vivo use of siRNAs-II. Mol. Ther. 20, 483–512 (2012). This paper describes advances in siRNA biochemistry for in vivo use.
Bartlett, D. W. & Davis, M. E. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucl. Acids Res. 34, 322–333 (2006).
Bartlett, D. W. & Davis, M. E. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotech. Bioeng. 99, 975–985 (2008).
Yuan, T. L. et al. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov. 4, 1182–1197 (2014). This paper nicely demonstrates the in vivo use of multiple different siRNAs within the same nanoparticle and the enhanced efficacy that can be obtained from such an approach.
Koldehoff, M., Steckel, N. K., Beelen, D. W. & Elmaagacli, A. H. Therapeutic application of small interfering RNA directed against BCR–ABL transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin. Exp. Med. 7, 47–55 (2007).
Molitoris, B. A. et al. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J. Am. Soc. Nephrol. 20, 1754–1764 (2009).
Petros, R. A. & DeSimone, J. M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9, 615–627 (2010).
Coelho, T. et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369, 819–829 (2013). This study reports clinical results for lipid-based siRNA delivery to the liver.
Fitzgerald, K. et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blinded placebo-controlled, Phase 1 trial. Lancet 383, 60–68 (2014). This study reports results from a Phase I trial that utilized a lipid-based formulation of siRNA for delivery to the liver.
Nair, J. K. et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136, 16958–16961 (2014).
Golan, T. et al. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget [online], (2015).
Farooqi, A. A., Rehman, Z. & Muntane, J. Antisense therapeutics in oncology: current status. Onco. Targets Ther. 7, 2035–2042 (2014).
Davis, M. E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067–1070 (2010). This paper reported the first example of the RNAi mechanism of action in a human from the delivery of siRNA via a polymer-based nanoparticle, that localized in human tumours in amounts that correlated with the dose levels systemically administered to the patients.
Zuckerman, J. E. et al. Correlating animal and human Phase Ia/Ib clinical data with CALAA 01, a targeted, polymer-based nanoparticle containing siRNA. Proc. Natl Acad. Sci. USA 111, 11449–11454 (2014). This paper summarizes all the clinical and preclinical results with CALAA 01.
Tabernero, J. et al. First in humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 3, 406–417 (2013). This study reports the first human results with ALN-VSP, a lipid-based formulation of two siRNAs. It is also the first example of two siRNAs used in the clinic.
Strumberg, D. et al. Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int. J. Clin. Pharm. Ther. 50, 76–78 (2012).
Schultheis, B. et al. First in human Phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. J. Clin. Oncol. 32, 4141–4148 (2014). This paper presents the first human data with Atu027, a lipid-based formulation of siRNA.
Ramanathan, R. K. et al. A Phase 1 dose escalation study of TKM 080301, a RNAi therapetuic directed against PLK1, in patients with advanced solid tumors. J. Clin. Oncol. 31 (Suppl), TPS2621 (2013).
Tolcher, A. W. et al. A Phase 1 study of the BCL2 targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors. Cancer Chemoth. Pharm. 73, 363–371 (2014).
Davis, M. E. The first targeted delivery of siRNA in humans via a self-assembling cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 6, 659–668 (2009).
Davis, M. E. Fighting cancer with nanoparticle medicines — the nanoscale matters. MRS Bull. 37, 828–835 (2012).
Grimm, D. et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537–541 (2006).
Heidel, J. D. et al. Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin. Cancer Res. 13, 2207–2215 (2007).
Barros, S. A. & Gollob, J. A. Safety profile of RNAi nanomedicines. Adv. Drug Deliv. Rev. 64, 1730–1737 (2012)
Judge, A. D. et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J. Clin. Invest. 119, 661–673 (2009).
Sioud, M. Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2′-hydroxyl uredines in immune responses. Eur. J. Immunol. 36, 1222–1230 (2006).
Heidel, J. D. et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase submit M2 siRNA. Proc. Natl Acad. Sci. USA 104, 5715–5721 (2007).
Inaba, S. et al. Atelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals. Mol. Ther. 20, 356–366 (2012).
Moyano, D. F. et al. Nanoparticle hydrophobicity dictates immune response. J. Am. Chem. Soc. 134, 3965–3967 (2012).
Hickerson, R. P. et al. Stability study of unmodified siRNA and relevance to clinical use. Oligonucleotides 18, 1–10 (2008).
Bartlett, D. W. & Davis, M. E. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol. Bioeng. 97, 909–921 (2007).
Zuckerman, J. E., Hsueh, T., Koya, R. C., Davis, M. E. & Ribas, A. siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide. J. Invest. Derm. 131, 453–460 (2011).
Cheng, Z. et al. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 338, 903–910 (2012).
Hu Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E. & Triche, T. J. Sequence-specific knockdown of EWS-FL1 by targeted, nonviral delivery of small interfering, RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65, 8984–8992 (2005).
Bartlett, D. W., Su, H., Hildebrandt, I. J., Weber, W. A. & Davis, M. E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl Acad. Sci. USA 104, 15549–15554 (2007).
Sykes, E. A. et al. Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency. ACS Nano. 8, 5696–5706 (2014).
Senzer, N. et al. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol. Ther. 21, 1096–1103 (2013).
Bertrand, N. et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Del. Rev. 66, 2–25 (2014).
Zuckerman, J. E., Choi, C. H. J., Han, H. & Davis, M. E. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc. Natl Acad. Sci. USA 109, 3137–3142 (2012).
Naeye, B. et al. In vivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier. Biomaterials 34, 2350–2358 (2013).
Song, G., Wu, H., Yoshino, K. & Zamboni, W. C. Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs. J. Liposome Res. 22, 177–192 (2012).
Eliasof, S. et al. Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc. Natl Acad. Sci. USA 110, 15127–15132 (2013). This paper reports correlations between preclinical and clinical data for the polymer-based, drug-containing nanoparticle denoted CRLX101.
Venditto, V. J. & Szoka, F. C. Jr. Cancer nanomedicines: so many papers and so few drugs! Adv. Drug Del. Rev. 65, 80–88 (2013).
Stein, C. A. & Goel, S. Therapeutic oligonucleotides: the road not taken. Clin. Cancer Res. 17, 6369–6372 (2011).
[No authors listed.] Time to deliver. Nat. Biotech. 32, 961 (2014).
Merritt, W. M., Bar-Eli, M. & Sood, A. K. The dicey role of Dicer: implications for RNAi therapy. Cancer Res. 70, 2571–2574 (2010).
Merritt, W. M. et al. Dicer, drosha, and outcomes in patients with ovarian cancer. N. Engl. J. Med. 359, 2641–2650 (2008).
Caffrey, E. et al. Prognostic significance of deregulated dicer expression in breast cancer. PLoS ONE 8, e83724 (2013).
Daige, C. L. et al. Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer. Mol. Cancer Ther. 13, 2352–2360 (2014).
Cheng, C. J. et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 518, 107–110 (2015).
Pennisi, E. The CRISPR craze. Science 341, 833–836 (2013).
Dounda, J. A. & Charpenter, E. The new frontier of genome engineering with CRISPER Cas9. Science 346, 1258096 (2014).
Tang, L. et al. Investigating the optimal size of anticancer nanomedicine. Proc. Natl Acad. Sci. USA 111, 15344–15349 (2014).
Adjei, I. M. et al. Heterogeneity in nanoparticles influences biodistribution and targeting. Nanomedicine 9, 267–278 (2014).
Zhang, J. et al. Assessing the heterogeneity level in lipid nanoparticles for siRNA delivery: size-based separation, compositional heterogeneity, and impact on bioperformance. Mol. Pharm. 10, 397–405 (2013).
Maier, M. A. et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticle for systemic delivery of RNAi therapeutics. Mol. Ther. 21, 1570–1578 (2013).
Whitehead, K. A. et al. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat. Commun. 5, 4277 (2014).
Barrett, S. E. et al. Development of a liver-targeted siRNA delivery platform with a broad therapeutic window utilizing biodegradable polypeptide-based polymer conjugates. J. Control. Release 183, 124–137 (2014).
Lane, L. A., Qian, X., Smith, A. M. & Nie, S. Physical chemistry of nanomedicine: understanding the complex behavior of nanoparticles in vivo. Annu. Rev. Phys. Chem. 66, 521–547 (2015).
Landesman-Milo, D. & Peer, D. Toxicity profiling of several common RNAi-based nanomedicines: a comparative study. Drug Deliv. Transl. Res. 4, 96–103 (2014).
Hwang, T., Aljuffali, I. A., Lin, C., Chang, Y. & Fang, J. Cationic additives in nanosystems activate cytotoxicity and imflammatory response of human neutrophils: lipid nanoparticles versus polymeric nanoparticles. Int. J. Nanomed. 10, 371–385 (2015).
Robbins, G. R. et al. Analysis of human innate immune responses to PRINT fabricated nanoparticles with cross validation using a humanized mouse model. Nanomedicine 11, 589–599 (2015).
Li, L. et al. Tumor vasculature is a key determinant of the efficiency of nanoparticle-mediated siRNA delivery. Gene Ther. 19, 775–780 (2012).
Cabral, H. et al. Accumulation of sub 100nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotech. 6, 815–823 (2011).
Prabhaker, U. et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 73, 2412–2417 (2013).
Koukourakis, M. I. et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J. Clin. Oncol. 17, 3512–3521 (1999).
Karrington, K. J. et al. Effective targeting of solid tumors in patients with locally advanced cancer by radiolabeled pegylated liposomes. Clin. Cancer Res. 7, 243–254 (2001).
Cuellar, T. L. et al. Systemic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB–siRNA conjugates. Nucleic Acids Res. 43, 1189–1203 (2015).
Weiss, G. J. et al. First in human Phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest. New Drugs 31, 986–1000 (2013).
Suetsugu, A. et al. Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models. Adv. Drug Del. Rev. 65, 383–390 (2013).
Sehgal, A. Chen, Q. Gibbings, D., Sah, D. W. Y. & Bumcrot, D. Tissue-specific gene silencing monitored in circulating RNA. RNA 20, 1–7 (2014).
Antanaviciute, I. et al. Long-distance communication between laryngeal carcinoma cells. PLoS ONE 9, e99196 (2014).
Melo, S. A. et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell 26, 707–721 (2014).
Hannafon, B. N. & Ding, W. Intercellular comminucaiton by exosome-derived microRNAs in cancer. Int. J. Mol. Sci. 14, 14240–14269 (2013).
Roberts, C. T. Jr & Kurre, P. Vesicle trafficking and RNA transfer add complexity and connectivity to cell–cell communication. Cancer Res. 73, 3200–3205 (2015).
Dienstmann, R. et al. Safety and activity of the first in class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer. Cancer Discov. 5, 598–609 (2015).
Sharma, S. V., Bell, D. W., Settleman, J. & Haber, D. A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7, 169–181 (2007).
Fedornko, I. V., Gibney, G. T., Sondak, V. K. & Smalley, K. S. M. Beyond, BRAF: where next for melanoma therapy? Br. J. Cancer 112, 217–226 (2015).
M.E.D. has stock in and is a consultant to Cerulean Pharma, Avidity NanoMedicines and Intellia Therapeutics.
- RNA interference
(RNAi). An intrinsic pathway in eukaryotic cells by which short pieces of RNA are able to induce the degradation of mRNA transcripts containing a complementary sequence.
- Small interfering RNA
(siRNA). Synthetic double-stranded RNA molecules approximately 21–23 nucleotides long that are capable of engaging the intrinsic RNAi pathway when delivered to the cellular cytoplasm.
- Systemic administration
A route of administration of a drug into the circulatory system so that the entire body is affected. In the nanoparticle therapeutic field, this usually refers to intravenous administration.
- RNA-induced silencing complex
(RISC). The protein complex responsible for the identification and destruction of the target mRNA when engaged by siRNA.
Generally refers to particles between 1 and 100 nm in size.
A broad category of drug delivery vehicles based on a backbone of lipid bilayers.
A large group of proteins, peptides or glycoproteins that are secreted by specific cells of the immune system. Cytokines are a category of signalling molecules that mediate and regulate immunity, inflammation and haematopoiesis.
An innate part of the mammalian immune system that complements the ability of antibodies and phagocytic cells to clear pathogens from an organism.
- eastern Cooperative Oncology Group performance status
A quantification of the general well-being, daily activity and physical ability of a patient with cancer. In the setting of a clinical trial, set performance status cut-off levels are one criterion used to determine eligibility for trial enrolment and treatment.
The study of the biochemical and physiological effects of a drug on the body, including mechanistic action, duration of action, therapeutic effects and toxicities.
The movement of a drug into, through and out of the body; that is, its absorption, bioavailability, distribution, metabolism and excretion.
- Enhanced permeability and retention effect
A phenomenon whereby macromolecules and nanoparticles passively accumulate within tumour tissue from the bloodstream. The mechanism behind this phenomenon is poorly understood and is thought to be partially due to the increased permeability of tumour vasculature and poor tumour lymphatic drainage.
- CRISPR system
An RNA-guided gene-editing platform that utilizes the bacterial protein Cas9 and a synthetic guide RNA to introduce a double-stranded DNA break at a specific location within the genome.
About this article
Cite this article
Zuckerman, J., Davis, M. Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat Rev Drug Discov 14, 843–856 (2015). https://doi.org/10.1038/nrd4685
This article is cited by
European Journal of Medical Research (2022)
Molecular Cancer (2022)
CD73 downregulation by EGFR-targeted liposomal CD73 siRNA potentiates antitumor effect of liposomal doxorubicin in 4T1 tumor-bearing mice
Scientific Reports (2022)
Clinical and Translational Oncology (2022)
A smart multiantenna gene theranostic system based on the programmed assembly of hypoxia-related siRNAs
Nature Communications (2021)